| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.02. | Orexo AB: Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs | 264 | GlobeNewswire (Europe) | The Board of Orexo AB (publ) has today decided to convert 416,417 Class C shares into ordinary shares and to subsequently convey 416,417 ordinary shares to certain participants in the long-term incentive... ► Artikel lesen | |
| 05.02. | Orexo AB: Orexo Interim Report Q4 2025, incl. Full Year Report | 90 | GlobeNewswire (Europe) | Turning a transformative deal into new opportunitiesQ4 2025 highlights›Dexcel Pharma USA aquired all rights to Zubsolv® US on December 31, at a purchase price of USD 91 m plus the value of inventory... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 22.12.25 | Orexo AB: Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv | 236 | GlobeNewswire (Europe) | · An asset purchase agreement has been signed with Dexcel Pharma USA, which will acquire the full rights to Zubsolv® in the US, at a purchase price of USD 91 million plus the value of inventory at closing... ► Artikel lesen | |
| 23.10.25 | Earnings Call zu Orexo AB: Aktie bricht nach Umsatzverfehlung im dritten Quartal 2025 ein | 2 | Investing.com Deutsch | ||
| 23.10.25 | Orexo Q3 2025 slides: Revenue miss overshadows AmorphOX pipeline progress | 1 | Investing.com | ||
| 23.10.25 | Orexo AB Q3 Loss Narrows | 1 | RTTNews | ||
| 23.10.25 | Orexo AB: Orexo Q3 2025 Interim Report | 169 | GlobeNewswire (Europe) | Unlocking the potential of the AmorphOX® technologyQ3 2025 highlights› Total net revenues of SEK 118.7 m (136.5)› EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with... ► Artikel lesen | |
| 01.10.25 | Orexo AB: Orexo strengthens innovation and research with move to new premises | 135 | GlobeNewswire (Europe) | Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move... ► Artikel lesen | |
| 30.09.25 | Orexo US Awarded $8M in Funding by BARDA | 1 | Contract Pharma | ||
| 29.09.25 | Orexo AB: Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership | 363 | GlobeNewswire (Europe) | Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical... ► Artikel lesen | |
| 05.09.25 | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 1.037 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
| 29.08.25 | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 414 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen | |
| 16.07.25 | Orexo AB: Orexo Q2 2025 Interim Report | 304 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen | |
| 02.06.25 | Orexo to present clinical data for OX640 at the EAACI Congress | 330 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of severe allergic reactions (including anaphylaxis) and is based on the proprietary AmorphOX® technologyEAACI... ► Artikel lesen | |
| 06.05.25 | Orexo AB: Orexo Q1 2025 Interim Report | 331 | GlobeNewswire (Europe) | Q1 2025 highlights› Total net revenues of SEK 146.2 m (139.3)› EBITDA of SEK 5.9 m (15.9)› Net earnings of SEK -15.9 m (-8.9)› US Commercial segment net revenues of SEK 133.0 m (129.3), in local currency... ► Artikel lesen | |
| 10.04.25 | Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology | 505 | PR Newswire | The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,150 | -1,25 % | Is Aurora Cannabis Stock Ready to 10X in the Next Pot Boom? | ||
| ABBVIE | 199,00 | -0,75 % | AbbVie Reports Positive Phase 3 Results For Risankizumab In Crohn's Disease | WASHINGTON (dpa-AFX) - AbbVie (ABBV) on Monday announced positive results from the Phase 3 AFFIRM study evaluating subcutaneous risankizumab in moderately to severely active Crohn's disease.... ► Artikel lesen | |
| TILRAY BRANDS | 6,390 | -1,84 % | MDMA-Herausforderer Bioxyne punktet mit 112% Umsatzplus. Und was macht Tilray? | ||
| BRISTOL-MYERS SQUIBB | 52,88 | -0,84 % | Bristol Myers Squibb declares $0.63 quarterly dividend | ||
| TEVA | 28,400 | -1,73 % | Teva Pharmaceutical Industries Ltd: Teva to Present at the Upcoming Investor Conferences in March | PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will... ► Artikel lesen | |
| BAUSCH HEALTH | 5,041 | -1,04 % | Bausch Health Companies Inc. - 8-K, Current Report | ||
| BIONANO GENOMICS | 1,140 | 0,00 % | Bionano Genomics: Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress | SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. "Over the last year, we have taken... ► Artikel lesen | |
| OPKO HEALTH | 1,060 | 0,00 % | OPKO Health, Inc.: OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results | MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces... ► Artikel lesen | |
| JAGUAR HEALTH | 0,805 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.02.2026 | Das Instrument UZ9 CA4577022078 INSPIRATION ENERGY CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 27.02.2026 und ex Kapitalmassnahme am 02.03.2026 The instrument UZ9 CA4577022078 INSPIRATION ENERGY... ► Artikel lesen | |
| KEENOVA THERAPEUTICS | - | - | Keenova Therapeutics: Keenova Announces New Dupuytren's Contracture Survey Presentation About Patient Perceptions and Treatment Outcomes | Analysis to Be Presented at the American Association for Hand Surgery Meeting
DUBLIN, Jan. 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that... ► Artikel lesen | |
| AVALO THERAPEUTICS | 15,020 | -1,96 % | Avalo Therapeutics: TD Cowen bestätigt Kaufempfehlung angesichts von Phase-II-Chancen | ||
| BAYER | 38,775 | -4,52 % | MustGrow Biologics und die Partnerschaft mit Bayer: Darum steht die Aktie erst am Anfang | Die globale Landwirtschaft steht vor einem Paradox. Sie muss mehr Menschen ernähren, aber mit weniger chemischen Mitteln. Weltweit sind in 162 Ländern inzwischen 460 Pestizide verboten oder eingeschränkt.... ► Artikel lesen | |
| NOVO NORDISK | 31,535 | -1,97 % | Hims & Hers nach Preisattacke auf Novo Nordisk mit Zahlen: Aktie rauscht erneut in den Keller | Die US-amerikanische Telemedizin-Plattform Hims & Hers hat am Montag nach Börsenschluss die Zahlen für das vierte Quartal respektive Gesamtjahr 2025 vorgelegt. Überschattet werden die Ergebnisse und... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 15,060 | 0,00 % | Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies | Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform
Lead candidates ATR 1072... ► Artikel lesen | |
| MERCK KGAA | 122,65 | -2,85 % | Big Blue IBM, Fastly & Merck KGaA - Was sagen Charts UND Fundamentaldaten wirklich? |